Loading organizations...
Bluedrop Medical is a Galway, Ireland-based medical technology company that develops an AI-powered temperature monitoring device for at-home daily foot scans to detect early signs of diabetic foot ulcers. The remote monitoring system completes assessments in under 30 seconds, allowing clinics to review patient data to prevent infections and amputations in high-risk diabetic populations suffering from peripheral neuropathy. The enterprise has raised €16 million in total funding to date, including a €10.5 million oversubscribed venture capital round in March 2023 co-led by Atlantic Bridge and Elkstone. Additional financial backing comes from the European Innovation Council Fund and Furthr VC, supporting the commercialization of the hardware across Europe and the United States while creating 25 new jobs to expand operations. Bluedrop Medical was founded in 2015 by former Medtronic engineers Chris Murphy and Simon Kiersey.
Bluedrop Medical has raised $12.2M across 2 funding rounds.
Bluedrop Medical has raised $12.2M in total across 2 funding rounds.
Bluedrop Medical has raised $12.2M across 2 funding rounds. Most recently, it raised $1.2M Undisclosed in February 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 2, 2026 | $1.2M Undisclosed | Enterprise Ireland | — | Announced |
| Mar 1, 2023 | $11M Seed | — | Atlantic Bridge, Elkstone, Finch Capital, SOSV | Announced |
Bluedrop Medical is a medtech company developing devices to prevent diabetic foot ulcers and amputations. Founded in 2015 and headquartered in Galway, Ireland, it offers the OneStep Foot Scanner, a home-use device that scans feet in 30 seconds to capture temperature data and high-resolution images, sending them to the cloud for AI-driven analysis via the EveryStep Monitoring Service.[1][2][4] This targets diabetic patients—who number nearly half a billion worldwide, with up to 25% at risk of ulcers—and healthcare providers, addressing the massive burden of ulcers leading to hundreds of thousands of amputations annually by enabling early detection and intervention.[3][1] The company has raised over $15M, holds 3 patents in areas like neurological disorders, and has received European Innovation Council support, signaling strong growth momentum in connected health.[1][2][5]
Bluedrop Medical was founded in 2015 by Chris Murphy and Simon Kiersey, former Medtronic R&D engineers, in Galway, Ireland.[1][2] The idea emerged from in-clinic primary research revealing the heavy toll of diabetic foot ulcers and amputations due to peripheral neuropathy, which dulls foot sensation and prevents early warning.[1] Leveraging their life sciences and medical device expertise, they created a scanner to restore that feedback by collecting daily temperature and image data for ulcer risk assessment.[1][2] Early refinement came from direct input with diabetic patients and providers, yielding a simple, elegant solution.[1] Chris Murphy, a James Dyson Award winner and Ireland's Best Young Entrepreneur regional honoree, has driven fundraising and product design; the team includes wound care pioneer Dr. Scott, who founded one of the U.S.'s first integrated wound facilities in 1985.[1]
Bluedrop rides the connected health and remote monitoring wave, accelerated by diabetes prevalence (nearly 500M cases globally) and post-pandemic telehealth adoption, where early DFU detection can slash amputation rates and healthcare costs.[3][1] Timing aligns with AI-driven medtech growth, IoT integration, and regulatory support like the EIC fund, positioning it amid trends in preventive care for chronic diseases.[2][5] Market forces favor it: rising diabetic populations, high ulcer recurrence (millions yearly), and demand for home-based tools that cut clinic visits.[3][4] Bluedrop influences the ecosystem by advancing diabetic foot disease tech, inspiring scalable, patient-centric solutions and contributing to Ireland's medtech hub status alongside investors like Elkstone.[2]
Bluedrop Medical stands poised for expansion with its validated scanner, recent funding, and patents enabling global scaling into underserved diabetic markets. Upcoming trends like AI enhancements in wound prediction and broader IoT health platforms will amplify its reach, potentially partnering with insurers for population-level deployment. Its influence may evolve from niche innovator to standard in DFU prevention, directly curbing unnecessary amputations as adoption grows—fulfilling its core mission from day one.[1][3]
Bluedrop Medical has raised $12.2M in total across 2 funding rounds.
Bluedrop Medical's investors include Enterprise Ireland, Atlantic Bridge, Elkstone, Finch Capital, SOSV.
